Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 2Thoracic 1Gastrointestinal 1Breast 1

Conditions

Esophageal Stenosis 2Stomach Neoplasms 1Ovarian Neoplasms 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Hepatocellular 1Biliary Tract Neoplasms 1Barrett Esophagus 1

Interventions

pembrolizumab 29Carboplatin 10Surveys and Questionnaires 9Paclitaxel 9Trastuzumab 8Nivolumab 8Cisplatin 8Taxes 7Gemcitabine 7Bevacizumab 6Specimen Handling 5Oxaliplatin 5Irinotecan 5Fluorouracil 5Cetuximab 5Biopsy 5spartalizumab 4Leucovorin 4Ipilimumab 4Docetaxel 4Cyclophosphamide 4tisotumab vedotin 3fludarabine 3durvalumab 3atezolizumab 3aldesleukin 3X-Rays 3Psychiatric Rehabilitation 3Magnetic Resonance Spectroscopy 3Interviews as Topic 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Endometrial Neoplasms × Prednisolone × Gastrointestinal × Clear all
NCT05489211 2026-03-19

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

AstraZeneca

Phase 2 Recruiting
454 enrolled
GastrointestinalGynecologic

Biliary Tract Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡